Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 7/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104000 | 0.89 | S1PR3 (0.75) | S1PR3PLA2G2A | |
| SCHEMBL805707 | 0.88 | MEN1 (0.67) | S1PR3PLA2G2AMAPTPKMGAA | |
| SCHEMBL805710 | 0.85 | S1PR3 (0.80) | S1PR3 | |
| SCHEMBL10104224 | 0.85 | S1PR3 (0.58) | S1PR3PLA2G2AMAPTPKMGAA | |
| SCHEMBL805632 | 0.84 | MAPT (0.59) | S1PR3PLA2G2AMAPTPKMGAA | |
| SCHEMBL290764 | 0.81 | PLA2G2A (0.67) | S1PR3PLA2G2AMAPTPKMGAA | |
| SCHEMBL8235996 | 0.81 | MEN1 (0.62) | S1PR3PLA2G2AMAPTPKMGAA | |
| SCHEMBL14880137 | 0.80 | MAPT (0.74) | S1PR3PLA2G2AMAPTPKMGAA | |
| SCHEMBL805711 | 0.78 | S1PR3 (0.58) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL805692 | 0.77 | S1PR3 (0.78) | S1PR3MAPTPKMGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | claimed |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | DONELLO JOHN E | 2011-01-13 | — | — | US | claimed |
| EP-2262497-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | Allergan, Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| US-7737173-B2 | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2010-06-15 | — | — | US | claimed |
| WO-2009117335-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | claimed |
| EP-1984334-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2007095561-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2007-08-16 | — | — | US | claimed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-1984334-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007095561-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007095561-A2 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885PLA2G2A 188/4885MAPT 3312/4885 |
| US-20110009453-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PLA2G2A 254/4885MAPT 2739/4885 |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PLA2G2A 92/4885MAPT 3541/4885 |
| US-20070191313-A1 | INDOLE-3-CARBOXYLIC ACID AMIDE, ESTER, THIOAMIDE AND THIOL ESTER COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PLA2G2A 587/4885MAPT 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.